Hemophilia B – Landscape & Forecast – Disease Landscape & Forecast (G7)

Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in noninhibitor patients) and bypass agents (in inhibitor patients). The main goal of factor IX prophylaxis and bypass agent treatment is to improve the quality of life of patients by reducing the frequency and severity of bleeding episodes. The hemophilia B therapy market will be transformed over the next 10 years owing to the entry of gene therapies and nonfactor therapies. In November 2022, the FDA approved Hemgenix (CSL Behring), the first gene therapy for hemophilia B. Fidanacogene elaparvovec (Pfizer) is the other key gene therapy in development. Upcoming novel subcutaneous nonfactor therapies will offer effective alternatives to intravenously administered factor IX products and bypass agents. These nonfactor therapies include Pfizer’s marstacimab, Novo Nordisk’s concizumab, and Sanofi’s fitusiran. Supported by insights from thought leaders, we analyze the impact of new drug therapies on the treatment of hemophilia B.

Questions answered

• What is the current treatment landscape for hemophilia B? What are physicians’ experience and satisfaction levels with key current therapies intended for patients with and without inhibitors?
• How will hematologists differentiate between emerging therapies?
• What clinical roles will fitusiran, concizumab, marstacimab and gene therapy play in the evolving hemophilia B treatment landscape, especially for patients with inhibitors?
• How will the factor IX concentrate market evolve? How will nonfactor treatments impact the multitude of brands competing for patient share?

Content highlights

Geography: United States, EU5, Japan

Primary research: 19 country-specific interviews with thought-leading hematologists; supported by survey data collected for this and other Clarivate research

Epidemiology: Diagnosed prevalence of hemophilia B +/- inhibitors by country, population segmentation by disease severity and inhibitor titer

Forecast: 10-year, annualized, drug-level sales and patient share of key hemophilia B therapies through 2033, segmented by brands and epidemiological subpopulations

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.